CDMO biologics capacity and manufacturing bottlenecks: navigating capacity constraints

Modern Catalyst

The biologics manufacturing landscape in 2025 faces a structural mismatch: demand for monoclonal antibodies, cell therapies, and specialty biologics continues to outpace available GMP capacity, forcing procurement teams to rethink vendor selection criteria and timeline expectations. This is not a temporary shortage. Industry observers confirm that capacity constraints reshape CDMO partnerships, with Shonna Scalfani, SVP of Global CMC at a leading pharma organization, noting that "the best CDMO on paper may not be the best partner for your organization"—a candid acknowledgment that technical capability alone no longer guarantees manufacturing access.

The root cause is multifaceted. Regulatory approval timelines for new bioreactor suites and fill-finish lines remain lengthy (18–36 months for FDA inspection and GMP sign-off), while capital investment in greenfield capacity has slowed relative to pipeline growth. Simultaneously, reshoring initiatives and geopolitical supply-chain fragmentation have created competing demands on existing facilities. Policy tools for API manufacturing capacity reveal that investment incentives alone—tax credits, grants, or tariff relief—do not move the needle without complementary regulatory streamlining and workforce development. Gerren McHam, VP of Government and External Affairs at the API Innovation Center, underscores that reshoring API manufacturing requires structural policy reform, not just capital.

Within this constrained environment, two technological trends are emerging as partial relief valves. First, continuous processing and membrane-based downstream alternatives are gaining traction: WuXi Biologics' peer-reviewed pilot data suggests that existing fed-batch facilities could achieve an eightfold improvement in downstream processing capacity by replacing column chromatography with membrane-based separation. This is significant because it allows CDMOs to unlock latent capacity without major capital expenditure—a critical advantage when new suites take years to qualify. Second, specialized niches like radiopharmaceuticals are attracting venture capital precisely because manufacturing bottlenecks create pricing power; AdvanCell's $315 million Series D explicitly targets the radiopharmaceutical industry's "biggest constraint"—manufacturing capacity—signaling that investors see capacity scarcity as a durable, defensible market dynamic.

Structural Impact

Vendor Selection: Capacity Now Trumps Cost

Procurement teams accustomed to optimizing for unit cost per gram or vial must recalibrate. When a CDMO's bioreactor suite is fully booked 18–24 months out, the lowest-cost quote becomes irrelevant if your program cannot access manufacturing slots. Capacity constraints force a reordering of CDMO selection priorities: available timeline, existing client load, and demonstrated ability to scale within your program's development window now rank alongside technical capability and regulatory history.

This shift has three practical consequences:

First, mid-tier and emerging CDMOs gain negotiating leverage. Smaller contract manufacturers with 500–2,000 L capacity and lower client density may offer faster timelines and more flexible scheduling than Tier-1 players (Lonza, Catalent, Samsung Biologics) whose suites are saturated. Procurement teams should expand vendor evaluation to include regional CDMOs and specialized boutique manufacturers, particularly for early-phase and Phase II programs where batch sizes are modest.

Second, long-term partnerships and capacity reservation agreements become standard. Rather than spot-market contracting, sponsors increasingly negotiate multi-year manufacturing agreements with capacity holds—effectively paying a premium for guaranteed access. This reduces flexibility but eliminates the risk of being bumped by a higher-priority client mid-campaign.

Third, technology selection becomes a capacity lever. CDMOs investing in continuous downstream processing or membrane-based alternatives can squeeze additional throughput from existing equipment, making them more attractive partners even if their headline bioreactor volume is modest. Procurement teams should explicitly ask vendors about process intensification roadmaps and whether they are piloting continuous or membrane technologies.

Compliance and Regulatory Risk

Capacity constraints also create compliance friction. When CDMOs operate at or near full utilization, the margin for error shrinks. A single batch failure, equipment downtime, or regulatory inspection can cascade into missed timelines for multiple clients. Policy discussions around API manufacturing highlight that regulatory agencies themselves recognize this bottleneck; however, FDA and EMA inspections are not accelerating, and GMP compliance standards remain unchanged. This means CDMOs under capacity stress may cut corners on process validation, cleaning procedures, or documentation—risks that procurement teams must actively monitor through audit schedules and quality metrics.

Additionally, capacity scarcity incentivizes CDMOs to accept programs outside their core competency. A fill-finish specialist may take on a novel bioreactor project to fill idle capacity, increasing technical risk. Procurement teams should scrutinize vendor capability matrices and ask for evidence of successful execution in your specific modality (mAbs, ADCs, cell therapies, etc.) rather than assuming broad expertise.

Pricing Pressure and Cost Escalation

Paradoxically, capacity constraints are driving cost inflation even as sponsors seek cost reduction. CDMOs with limited availability can command premium pricing, and capacity reservation agreements lock in higher rates. Radiopharmaceutical manufacturing capacity is a case study: specialized facilities are so scarce that sponsors accept 20–30% cost premiums relative to conventional biologics manufacturing. Procurement teams should budget for 5–10% annual cost escalation in CDMO services through 2026, particularly for capacity-constrained modalities.

Strategic Blueprint

1. Map Your CDMO Landscape Early

Before selecting a manufacturing partner, conduct a capacity audit of your target CDMOs. Request:

Current bioreactor utilization (% of installed capacity in use)
Committed client load and expected release dates
Planned capacity additions and timelines
Technology roadmap (continuous processing, membrane alternatives, automation)

Use this data to segment CDMOs into three tiers: Immediate availability (≤6 months to manufacturing start), Medium-term (6–18 months), and Long-term (18+ months). Match your program timeline to the appropriate tier rather than forcing a fit with a preferred vendor.

2. Diversify Vendor Risk

Do not rely on a single CDMO for your entire manufacturing footprint. Negotiate with at least two qualified vendors for each manufacturing step (drug substance, fill-finish, packaging). This approach costs more upfront but protects against capacity shocks, regulatory actions, or geopolitical disruptions. Capacity constraints mean the best CDMO on paper may not deliver, so redundancy is insurance.

3. Invest in Process Intensification

Partner with CDMOs that are actively deploying continuous downstream processing or membrane-based technologies. These approaches can deliver 4–8× throughput gains from existing equipment, effectively creating "virtual capacity" without new capital. Request pilot data and timelines for technology transfer to your program.

4. Build Flexibility into Contracts

Negotiate manufacturing agreements with:

Tiered pricing: lower rates for guaranteed volume, higher rates for surge capacity
Capacity holds: reserved bioreactor or fill-finish slots, with a defined hold fee
Technology optionality: contractual rights to switch to continuous or membrane processing if available
Penalty clauses: mutual penalties for missed timelines, protecting both sponsor and CDMO

5. Engage Policy and Industry Advocacy

Policy tools for API and biologics manufacturing capacity remain underdeveloped. Procurement leaders should support industry advocacy for:

Accelerated FDA inspection timelines for new GMP suites (target: 12 months vs. current 24–36 months)
Tax incentives for CDMO capacity expansion in strategic regions
Workforce development programs to address technician and engineer shortages

These systemic changes will ease capacity constraints faster than any individual vendor selection strategy.

6. Monitor Emerging Niches

Specialized modalities like radiopharmaceuticals, cell therapies, and gene therapies are attracting venture capital precisely because manufacturing capacity is scarce and defensible. If your program targets these areas, expect to pay a capacity premium. Conversely, if you have flexibility in modality selection, conventional mAbs and recombinant proteins offer more abundant CDMO capacity and lower costs.